DEVELOPMENT OF A DENGUE VACCINE

登革热疫苗的开发

• 批准号: 7958791
• 负责人: Jorge E Osorio
• 金额: $ 4.68万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7958791
• 关键词: Animal Model; Centers for Disease Control and Prevention (U.S.); Clinical; Computer Retrieval of Information on Scientific Projects Database; Dengue; Dengue Virus; Development; Funding; Grant; Human; Institution; Population; Primates; Research; Research Personnel; Resources; Source; Testing; United States National Institutes of Health; Vaccines; Wisconsin; design; nonhuman primate; pre-clinical; vaccine development

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: To develop a vaccine for dengue viruses. Dengue viruses threaten over a third of the world's population and cause an estimated 100 - 150 million cases of dengue fever every year. InViragen's dengue vaccine was designed by collaborators at the Centers for Disease Control and Prevention (CDC) to protect against all four of the dengue viruses. The vaccine has been shown to be safe and effective in preclinical animal models. We have set up nonhuman primate animal models to test an experimental dengue vaccine for human clinical development. We are exploring preclinical development of a chimeric tetravalent vaccine.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目的：研制登革病毒疫苗。 登革热病毒威胁着世界三分之一以上的人口，每年估计造成1亿至1.5亿例登革热病例。InViragen的登革热疫苗是由美国疾病控制和预防中心（CDC）的合作者设计的，可以预防所有四种登革热病毒。该疫苗已在临床前动物模型中显示出安全有效。 我们已经建立了非人灵长类动物模型来测试用于人类临床开发的实验性登革热疫苗。我们正在探索嵌合四价疫苗的临床前开发。